Meta-analysis confirms rasagiline efficacy in Parkinson's disease

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Rasagiline (Azilect), a selective inhibitor of monoamine oxidase B, reduces a variety of symptoms of Parkinson's disease.

Why this matters

  • Individual trials of rasagiline for Parkinson's disease have generally been small.

Key results

  • Relative to peers given placebo, pa...